Last reviewed · How we verify

Auryxia — Competitive Intelligence Brief

Auryxia (FERRIC CITRATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ferric citrate. Area: Hematology.

marketed ferric citrate Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Auryxia (FERRIC CITRATE) — Keryx Biopharms. Auryxia works by binding to phosphate in the gut, reducing its absorption, and also providing iron to the body.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Auryxia TARGET FERRIC CITRATE Keryx Biopharms marketed ferric citrate 2014-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ferric citrate class)

  1. Keryx Biopharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Auryxia — Competitive Intelligence Brief. https://druglandscape.com/ci/ferric-citrate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: